12 completed. 12 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 12 | Completed 12 |
Follow Left Ventricular Hypertrophy: new trials by email Literature Review of Left Ventricular Hypertrophy trials Research Report on Left Ventricular Hypertrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Empagliflozin and Cardiac Remodelling in People Without Diabetes Empagliflozin, Placebo - Cardiovascular Diseases, Left Ventricular Hypertrophy | Phase 4 | Completed | Unity Health Toronto | 169 | 2021-04-01 | 2023-02-17 |
| Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease Amlodipine 5mg, Losartan, Losartan and Amlodipine - Aortic Stenosis, Aortic Regurgitation | Phase 4 | Completed | Hanmi Pharmaceutical Company Limited | 128 | 2018-10-18 | 2022-09-15 |
| Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients cardiac MRI, echocardiography with strain, Laboratory tests - Secondary Hyperparathyroidism, Chronic Kidney Disease Requiring Chronic Dialysis | Phase 4 | Completed | Rainer Oberbauer | 62 | 2017-10-01 | 2020-06-09 |
| Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes? Dapagliflozin, Placebo - Type 2 Diabetes, Left Ventricular Hypertrophy | Phase 4 | Completed | University of Dundee | 66 | 2017-02-14 | 2019-07-09 |
| MetfoRmin and Its Effects on Left Ventricular Hypertrophy in Normotensive Patients With Coronary Artery Disease Metformin XL, Placebo - Left Ventricular Hypertrophy, Insulin Resistance | Phase 4 | Completed | University of Dundee | 68 | 2015-03-01 | 2019-04-10 |
| Reduction of Left Ventricular Hypertrophy After Eplerenone Therapy Eplerenone 50 mg Tab - Hypertension,Essential, Obstructive Sleep Apnea | Phase 4 | Completed | Poznan University of Medical Sciences | 125 | 2014-07-01 | 2017-06-14 |
| Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study Allopurinol, Placebo (for allopurinol) - End Stage Renal Disease, Left Ventricular Hypertrophy | Phase 4 | Completed | University of Dundee | 80 | 2013-09-01 | 2016-11-04 |
| Effects Of Volume Control Guided by Body Composition Monitor (BCM) on Blood Pressure and Cardiac Condition in Hemodialysis Patients BCM, control group - Left Ventricular Hypertrophy | Phase 4 | Completed | Ege University | 126 | 2009-06-01 | 2013-09-09 |
| Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction? Placebo, Allopurinol - Kidney Disease, Left Ventricular Hypertrophy | Phase 4 | Completed | A. D. Struthers | 67 | 2008-01-01 | 2016-11-03 |
| Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy valsartan - Hypertension, Left Ventricular Hypertrophy | Phase 4 | Completed | Mustafa Kemal University | 38 | 2006-11-01 | 2011-08-30 |
| Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP) Candesartan, Felodipine - Hypertension, Left Ventricular Hypertrophy | Phase 4 | Completed | AstraZeneca | 315 | 2006-06-01 | 2012-04-02 |
| Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension amlodipine/benazepril - Hypertension, Left Ventricular Hypertrophy | Phase 4 | Completed | Novartis | 125 | 2004-07-01 | 2017-02-23 |
Hypertrophy, Left Ventricular (12) · Hypertension (4) · Aortic Valve Insufficiency (1) · Aortic Valve Stenosis (1) · Bronchiolitis Obliterans Syndrome (1) · Cardiovascular Diseases (1) · Coronary Artery Disease (1) · Diabetes Mellitus, Type 2 (1) · Essential Hypertension (1) · Hyperparathyroidism, Secondary (1) · Insulin Resistance (1) · Kidney Diseases (1) · Kidney Failure, Chronic (1) · Prediabetic State (1) · Sleep Apnea, Obstructive (1)
Cardiomegaly (12) · Heart Diseases (12) · Hypertrophy (12) · Pathological Conditions, Anatomical (12) · Pathological Conditions, Signs and Symptoms (12) · Cardiovascular Diseases (11) · Vascular Diseases (6) · Endocrine System Diseases (3) · Diabetes Mellitus (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Glucose Metabolism Disorders (2) · Male Urogenital Diseases (2) · Metabolic Diseases (2) · Nutritional and Metabolic Diseases (2)
Allopurinol (2) · Amlodipine (1) · Clinical Laboratory Techniques (1) · Control Groups (1) · Echocardiography (1) · Eplerenone (1) · Felodipine (1) · Losartan (1) · Tablets (1) · Valsartan (1) · amlodipine-losartan drug combination (1) · benazepril (1) · candesartan (1) · candesartan cilexetil (1) · dapagliflozin (1)
University of Dundee (3) · A. D. Struthers (1) · AstraZeneca (1) · Ege University (1) · Hanmi Pharmaceutical Company Limited (1) · Mustafa Kemal University (1) · Novartis (1) · Poznan University of Medical Sciences (1) · Rainer Oberbauer (1) · Unity Health Toronto (1)
United Kingdom (4) · South Korea (2) · Turkey (Türkiye) (2) · Austria (1) · Canada (1) · Taiwan (1) · United States (1)
Allan D Struthers, BSc, MD, FRCP, FESC (1) · Allan D Struthers, BSc, MD, FRCP, FESC, FRSE (1) · Allan Struthers, MD, FRCP (1) · Andrzej Tykarski, Prof (1) · Chim Lang, MD (1) · Chim Lang, MD, FRCP (1) · Duk-Hyun Kang (1) · Ender Hur, MD (1) · Ercan Ok, MD (1) · Fatih Yalcin, M.D. (1) · Graeme Houston, FRCR, MBBCh (1) · Gulay Asci, MD (1) · JeeWoong Son, MD (1) · Matthias Lorenz, Priv.Doz. (1)
PMID 10450601, PMID 10678860, PMID 10908222, PMID 10940788, PMID 11208620, PMID 11422885, PMID 16376782, PMID 17494787, PMID 17921053, PMID 1798888, PMID 18404673, PMID 18458174, PMID 19687350, PMID 20016520, PMID 20411620, PMID 22306782, PMID 24107724, PMID 25545400, PMID 26208670, PMID 2698218, PMID 28835229, PMID 2936235, PMID 31651370, PMID 32578850, PMID 32905623, PMID 33825489, PMID 35559350, PMID 35872799, PMID 36335517, PMID 36398903, PMID 37729887, PMID 37932788, PMID 38006908, PMID 38997620
2014 (1), 2016 (1)